| First Author | Liu H | Year | 2019 |
| Journal | Biochem Biophys Res Commun | Volume | 514 |
| Issue | 3 | Pages | 913-918 |
| PubMed ID | 31084931 | Mgi Jnum | J:291110 |
| Mgi Id | MGI:6442904 | Doi | 10.1016/j.bbrc.2019.05.004 |
| Citation | Liu H, et al. (2019) Myofibroblast-specific YY1 promotes liver fibrosis. Biochem Biophys Res Commun 514(3):913-918 |
| abstractText | Liver fibrosis is a common consequence of various chronic hepatitis and liver injuries. The myofibroblasts, through the accumulation of extracellular matrix (ECM) proteins, are closely associated with the progression of liver fibrosis. However, the molecular mechanisms underlying transcriptional regulation of fibrogenic genes and ECM proteins in myofibroblasts remain largely unknown. Using tamoxifen inducible myofibroblast-specific Cre-expressing mouse lines with selective deletion of the transcription factor Yin Yang 1 (YY1), here we show that YY1 deletion in myofibroblasts mitigates carbon tetrachloride-induced liver fibrosis. This protective effect of YY1 ablation on liver fibrosis was accompanied with reduced expression of profibrogenic genes and ECM proteins, including TNF-alpha, TGF-beta, PDGF, IL-6, alpha-SMA and Col1alpha1 in liver tissues from YY1 mutant mice. Moreover, using the human hepatic stellate cell (HSC) line LX-2, we found that knockdown of YY1 in myofibroblasts by siRNA treatment diminished myofibroblast proliferation, alpha-SMA expression, and collagen deposition. Collectively, our findings reveal a specific role of YY1 in hepatic myofibroblasts and suggest a new therapeutic strategy for hepatic fibrosis-associated liver diseases. |
